Skip to content
Screener

BioMarin Pharmaceuticals BMRN Common Stock Shares Issued

Common Stock Shares Issued at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
60.9M+7.5%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
75.8M+2.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
205.9M
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$47.34M+15.0%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
105.3M
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
159.8M+9.7%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$13.33B+21.1%
Enterprise value$16.65B+60.1%
P/E37×-39.9×
P/S3.9×+0.3×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
ASSETSJune 30, 2026 / (unaudited)December 31, 2025 ⁽¹⁾
Other long-term liabilities209,815150,816
Total liabilities5,401,7501,507,023
Stockholders’ equity:
Common stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectively194192
Additional paid-in capital6,037,0195,956,582
Company common stock held by the Nonqualified Deferred Compensation Plan(11,233)(10,508)
Accumulated other comprehensive loss(8,783)(13,473)
Retained earnings304,495154,206

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's common stock shares issued?
BioMarin Pharmaceuticals (BMRN) reported common stock shares issued of 193.5M in Q2 2026.
How has BioMarin Pharmaceuticals's common stock shares issued changed year-over-year?
BioMarin Pharmaceuticals's common stock shares issued increased by 0.8% year-over-year, from 192M to 193.5M.
What is the long-term trend for BioMarin Pharmaceuticals's common stock shares issued?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's common stock shares issued has grown at a 1.1% compound annual growth rate (CAGR), from 181.7M to 192.3M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about BioMarin Pharmaceuticals's common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude